A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor-Reference-Cited by-同舟云学术

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Published:2017-02 Issue:5 Volume:116 Page:575-583
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bendell Johanna C,Javle Milind,Bekaii-Saab Tanios S,Finn Richard S,Wainberg Zev A,Laheru Daniel A,Weekes Colin D,Tan Benjamin R,Khan Gazala N,Zalupski Mark M,Infante Jeffrey R,Jones Suzanne,Papadopoulos Kyriakos P,Tolcher Anthony W,Chavira Renae E,Christy-Bittel Janna L,Barrett Emma,Patnaik Amita

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201710.pdf

Reference43 articles.

1. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26: 2139–2146.

2. Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K, Tsuneyoshi M (2002) c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 40: 269–278.

3. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14: 249–256.

4. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O’Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA (2011) Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 29: 2357–2363.

5. Bennasroune A, Gardin A, Aunis D, Cremel G, Hubert P (2004) Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol 50: 23–38.

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LC‐ESI‐MS/MS method validation for simultaneous quantification of FDA‐approved anticancer agents futibatinib and binimetinib in rat plasma: Insights from preclinical pharmacokinetics;Biomedical Chromatography;2024-09-05

2. The HOXC10/NOD1/ERK axis drives osteolytic bone metastasis of pan-KRAS-mutant lung cancer;Bone Research;2024-08-27

3. Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature;Drugs in R&D;2024-08-23

4. Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature;Supportive Care in Cancer;2024-08-23

5. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression;Acta Neuropathologica Communications;2024-08-10